Congenital heart diseaseCross-sectional study
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants
- Cross-sectional study
- prospective clinical registry
- multicentre
Authors' conclusion
The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation.
Study context
- Population
- Individuals who had undergone Fontan palliation, enrolled in the Fontan Outcomes Network (38 congenital heart centres, US and Canada), August 2022–August 2024
- Participants
- 1,121 individuals
Main finding
As reported in the abstract
Baseline characteristics
- Age
- mean 16.3±10.2 years
- Female
- 471 [42%]
- Hypoplastic left heart syndrome
- n=431 [38.5%]
- RV-dominant anatomy
- n=615 [54.9%]
- Extracardiac conduit (most frequent Fontan type)
- n=749 [66.8%]
- History of arrhythmia (increasing with age)
- 41.3% (n=463)
- Acquired comorbidities (burden increasing by age)
- 57.5% (n=645)
- Asthma
- n=132 [12%]
- Sleep apnea
- n=103 [9%]
- Antithrombotic medication use
- nearly universal
- Anxiety disorder
- 34.1% (n=382)
- Anxiety disorder, adults
- 48.1% (n=194 of 403)
- Antidepressants prescribed
- 11.8% (n=132)
- Antidepressants prescribed, adults
- 23.6% (n=95 of 403)
Observational data: associations, not effects.
Safety
Typical Fontan-related adverse events
- Any typical Fontan-related adverse event
- 59% (n=662)
- Chylous pleural effusions
- n=108 [9.6%]
- Fontan thrombosis
- n=79 [7.1%]
- Nonperioperative stroke
- n=73 [6.5%]
Original publication
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. Circulation. Published 25 March 2026. doi:10.1161/circulationaha.125.078152
Summarised from the published abstract; every number is checked against it